Deoxyshikonin

Research use only, not for human use.

Deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases.

Deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases. Deoxyshikonin enhances the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. Deoxyshikonin and dodecyl gallate show significantly synergic antimicrobial activity with penicillin in vivo and in vitro, and can effectively reduce nasopharyngeal and lung colonization caused by different penicillin-resistant pneumococcal serotypes.

Cell Viability Assay Cell Line:Caco-2, HCT116, DLD-1 and HT29 cells Concentration:6.25, 12.5, 25, 50 and 100?μg/mL Incubation Time:48?h Result:At low concentration inhibited the growth of human colonic cancer cells including DLD-1, HCT-116, Caco-2 and HT29 cells. Had IC50 values of 31.00??μM at 24?h, while 10.97?μM at 48?h in HT29 cells. Apoptosis Analysis Cell Line:HT29 cells Concentration:25, 50 and 100?μg/mL Incubation Time:24 or 48?hResult:The ratio of early apoptotic cells increased from 1% to 29% in a dose-dependent manner by being treated with 0-50?μg/mL at 48?h.Cell Cycle Analysis Cell Line:HT29 cells Concentration:25, 50 and 100?μg/mL Incubation Time:48?h Result:The percentage of G0/G1 cells increased from approximately 44% to 67% in HT29 cells after treatment with 0-50?μg/mL, accompanied by a significant decrease in the percentage of cells at S and G2/M phases.Western Blot Analysis Cell Line:HT29 and DLD-1 cell lines Concentration:25, 50 and 100?μg/mL Incubation Time:48?h Result:Exerted a decrease of PI3K, p-PI3K, Akt, p-Akt308 and mTOR proteins expression in HT29 and DLD-1 cell lines.

Animal Model:Male BALB/c nude mice of 10-14?g with DLD-1 cells Dosage:20?mg/kg Administration:Intraperitoneal injection; every two days for a total of 13 days Result:Markedly suppressed the growth of xenograft tumours on day 5, 9 and 11 with 20?mg/kg, while there were no significant changes in body weight of the mice.

Arnebin 7, Deoxyshikonin

Cell Cycle/DNA Damage

DNA/RNA Synthesis

Others

——

——

43043-74-9

272.3

C16H16O4

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (122.40 mM)

CC(=CCCC1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)C

1,4-Naphthalenedione, 5,8-dihydroxy-2-(4-methyl-3-pentenyl)-

(-20℃)

With Ice Pack

≥ 2 years